Sofdra (sofpironium topical gel) for excessive underarm sweating

At a glance

Mechanism of action

Sofpironium is a soft (locally-metabolized) sweat-reducing medicine that blocks acetylcholine at sweat-gland muscarinic receptors. The 'soft drug' design means the active form is rapidly converted to an inactive metabolite after entering whole-body circulation, reducing the whole-body sweat-reducing medicine burden compared with tertiary-amine alternatives.

FDA indication and population

Sofdra (sofpironium topical gel, 12.45%) is FDA-approved for the topical treatment of primary excessive underarm sweating in adults and pediatric patients 9 years and older. The CARDIGAN-1 and CARDIGAN-2 Phase 3 trials studied this population and indication.

Trial evidence

CARDIGAN-1 and CARDIGAN-2 were Phase 3 randomized, vehicle-controlled trials. The primary endpoint was the Excessive sweating Disease Severity Measure - Underarm, 7-day recall (HDSM-Ax-7), a patient-reported instrument scored 0-10. Secondary endpoints included gravimetric sweat production. The label reports day-43 response rates and gravimetric reductions.

How to apply

Sofdra is a gel applied once daily to clean, dry underarms. The label specifies application via a metered-dose dispenser to ensure consistent dose per axilla. Wash hands thoroughly after application to avoid inadvertent eye contact. Application to broken or freshly shaved skin should be avoided.

Common adverse reactions

The Sofdra label reports application-site reactions (most common) and whole-body sweat-reducing medicine effects (dry mouth, mydriasis, urinary hesitation, blurred vision). The soft-drug design is intended to reduce whole-body exposure, but sweat-reducing medicine adverse effects still occur and are screened for before prescribing.

Soft-drug pharmacology

The clinical rationale for a soft-drug sweat-reducing medicine is to concentrate effect at the application site while minimizing whole-body exposure. After absorption, sofpironium is converted to a less-active metabolite. In practice, the application-site sweat-reducing medicine effects (and the whole-body ones that do appear) overlap substantially with other sweat-reducing medicine drugs; the soft-drug design influences pharmacokinetics rather than producing a categorically different adverse-effect profile.

Practical considerations

• • Next step: topical gel via metered dispenser
• • Frequency: once daily for both axillae
• • Prescription required
• • FDA indication: primary excessive underarm sweating, age 9+
• • Region: underarm ONLY (off-label elsewhere)

Side effects and reasons this may not be safe for you

• • Application-site reactions (most common)
• • Dry mouth
• • Mydriasis if inadvertent eye contact
• • Urinary hesitation
• • Blurred vision
• • Constipation (less common)

Compare this option

• Compare: qbrexza vs sofdra →

Governed citations

Numbers and approved uses on this page link back to their sources governed in anna-pipeline. Each entry below is a packet bound to this treatment.

Frequently asked

Is Sofdra better than Qbrexza?

There is no head-to-head comparative trial between Sofdra and Qbrexza. Both are FDA-approved for the same indication in the same population. The molecule, dosage form (gel vs cloth), main result measured in the clinical trials (HDSM-Ax-7 vs ASDD), and adverse-event profile each differ. The choice typically depends on tolerability, prior experience with medicines that reduce sweating, and the prescribing clinician's preference. The /compare/qbrexza-vs-sofdra page walks through the side-by-side.

How long until Sofdra works?

Trial data report progressive improvement over weeks, with primary endpoint measurement typically at day 43. Patients often note partial improvement earlier; consistent daily application is needed for steady-state effect.

Why is Sofdra only approved for the underarms?

The CARDIGAN trials enrolled patients with primary excessive underarm sweating and the label reflects that scope. Other body regions have not been studied with the same trial design, and the absorption and irritation profiles of hand, foot, and facial skin differ enough that off-label use is not supported by the evidence base.

Reading paths

• Check your severity with the HDSS calculator →
• Body regions →
• How claims are governed →

When this treatment is usually considered